Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt small index

Kaposi Sarcoma: early-phase trial registry

11 of 14 indexed Kaposi Sarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 11 currently recruiting · #1,230 of 28,707 conditions by registered trial count

Kaposi Sarcoma: 14 US clinical trials tracked, 11 recruiting.

Kaposi Sarcoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.

Enrollment posture brief

Registry condition kaposi-sarcoma

OPEN 11 | RECR 79% | LATE 0 | EARLY 9 | RANK #1230 | SPON 7

Nearest open-share peer: Obesity Prevention (79% recruiting · 14 trials)

Kaposi Sarcoma (this)79%Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly28.6%Abscess7.1%
Open-enrollment share among volume-matched conditions near Kaposi Sarcoma

Kaposi Sarcoma lists 11 open slots (79% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Kaposi Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Kaposi Sarcoma is recruiting above its size-band peers.

    11 of 14 indexed trials (78.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Kaposi Sarcoma research.

    National Cancer Institute (NCI) accounts for 7 of 14 trials (50%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Kaposi Sarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 62 among the 14 trials that report a genuine target (sentinel values excluded). 11 of those (78.6%) plan for fewer than 100 participants.

  4. Kaposi Sarcoma splits between interventional and observational designs.

    9 interventional and 5 observational studies make up this index (64.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 24

Open and recent trials

14 total, page 1 of 1

RECRUITING 200 participants

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

AIDS Malignancy Consortium

NCT05663502

RECRUITING 150 participants

Natural History Study of Kaposi Sarcoma

National Cancer Institute (NCI)

NCT06375122

RECRUITING Phase 1 86 participants

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

National Cancer Institute (NCI)

NCT04941274

RECRUITING Phase 1 80 participants

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

National Cancer Institute (NCI)

NCT04303117

RECRUITING Phase 2 65 participants

A Study of sEphB4-HSA in Kaposi Sarcoma

Vasgene Therapeutics

NCT03993106

RECRUITING Phase 1 58 participants

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

National Cancer Institute (NCI)

NCT04902443

RECRUITING Phase 1 56 participants

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT05859074

RECRUITING Phase 2 55 participants

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

National Cancer Institute (NCI)

NCT07308886

RECRUITING Phase 2 41 participants

Trial of Ixazomib for Kaposi Sarcoma

AIDS Malignancy Consortium

NCT04305691

RECRUITING Phase 2 25 participants

Propranolol for the Treatment of Kaposi Sarcoma in Adults

Washington University School of Medicine

NCT06445166

RECRUITING 20 participants

Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial

Washington University School of Medicine

NCT06751355

ACTIVE NOT RECRUITING Phase 1 62 participants

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

National Cancer Institute (NCI)

NCT02659930

ACTIVE NOT RECRUITING 40 participants

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

National Cancer Institute (NCI)

NCT04742387

COMPLETED 394 participants

Development of Serologic Assays for Human Herpes Virus-8

National Institutes of Health Clinical Center (CC)

NCT00395278

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4

Named interventions

Most-linked intervention names on Kaposi Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

pomalidomide Drug
1 trials
SkinScan3D camera Device
1 trials
liposomal doxorubicin Drug
1 trials
sEphB4-HSA Drug
1 trials
CYT107 Drug
1 trials
Propranolol Hydrochloride Drug
1 trials
M7824 Drug
1 trials
PDS01ADC Drug
1 trials

US sites by state

Facility locations filed on Kaposi Sarcoma trials. A trial with sites in several states counts in each.

Maryland 10 trials
New York 3 trials
Missouri 3 trials
Florida 3 trials
California 3 trials
Texas 2 trials
Washington 1 trials
Utah 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Kaposi Sarcoma page

14 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kaposi Sarcoma condition card totals 14 registered trials; most-linked intervention pomalidomide; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.